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2Abstract
This study investigated the effects of baclofen, a GABAB agonist, on modulating drug seeking 
and drug reward in a novel model of reinstatement. To investigate drug seeking, rats were 
trained to nosepoke for cocaine infusions, given a drug holiday, and under a baclofen 
pretreatment (0, 0.2, 1, or 5 mg/kg i.p.), were exposed to an odor conditioned discriminative 
stimulus (DS+) that reinstated cocaine self-administration.  To investigate drug reward, an odor 
reactivity test was used.  Rats were tested for changes in odor preference after the acquisition, 
drug holiday, and reinstatement phases of self-administration behavior were each completed. 
Pretreatment with the low dose of baclofen (0.2) attenuated cocaine seeking primed by a 
conditioned DS+.  Medium doses (1.0) caused no change in drug seeking.  High doses (5.0) 
caused a reduction in drug seeking, but this was due to motor impairment.  No doses of baclofen 
had any affect on the rewarding properties of cocaine or cocaine-associated stimuli.  It can be 
concluded that GABAB receptors have no role in modulating the rewarding properties of drug 
rewards or drug-associated stimuli, but instead play a role in modulating drug seeking. In rats 
that were exposed to a drug in the past, low levels of GABAB receptor activation reduce drug-
seeking, while medium to high levels could have reduced dopamine levels to the point that 
increased drug seeking or motor impairment was seen.  
3Introduction
Drug-seeking behaviors are likely mediated by multiple neurotransmitters and 
motivational states.  GABAergic receptor activation is a potent modulator of drug craving, 
reward, and seeking.  A specific type of GABA receptors, GABAB, present in many limbic areas, 
may be responsible for this modulation. 
GABAergic system
There are three main types of GABA (gamma-aminobutyric acid) receptors:  GABAA, 
GABAB, and GABAC.  Little is known about GABAC receptors.  GABAA receptors are 
ionotropic, while GABAB receptors are metabotropic, which means GABAB activation has 
longer lasting effects (Misgeld 1995).  GABAB receptors act indirectly through G-protein 
coupling that closes calcium channels or opens potassium channels, while GABAA receptors act 
directly by opening chlorine channels (Bormann 1988).  The net result of GABAB activation is 
inhibition of neurotransmitter release, while GABAA activation results in neuronal inhibition 
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4(Misgeld 1995).  Low levels of GABA or GABAB agonists activate presynaptic GABAB
receptors, while high levels activate post-synaptic GABAB receptors (Yamada 1999). 
GABAA receptors have binding sites for GABA, alcohol, neurosteroids, anesthetics, 
barbiturates, and benzodiazepines.  In contrast, the GABAB receptor shows promise as an action 
site for a therapeutic because of its specificity.  Unlike GABAA receptors, which have multiple 
binding sites that can cause drug interactions when medications are combined with alcohol, for 
example, GABAB receptors bind specifically to GABA, GABAB agonists, and GABAB
antagonists.  GABAB receptors, unlike GABAA receptors, do not have binding sites for 
allopregnalone, which means that these receptors would not be affected by the changing levels of 
this neurosteroid during the female estrous cycle. Thus, GABAB agonists should have similar 
drug effects in females and males.
GABAB receptors are localized in several parts of the brain, including the VTA (ventral 
tegmental area), PFC (prefrontal cortex), BLA (basolateral amygdala), cerebellum, SN 
(substantia nigra), thalamus, and hippocampus. GABAergic neurons make up the majority (80%) 
of neurons in the NA and mainly act on GABAB receptors on DA cell bodies in the VTA (Kita 
1988). Supporting this, baclofen, a GABAB agonist, reduced stimulus-evoked elevations in DA 
release from the VTA to the PFC and NA (Kalivas 1990).  Baclofen infused into the PFC caused 
a decrease in extracellular DA in the PFC (Santiago 1993).  
Baclofen infused into the substantia nigra also decreased extracellular DA in the striatum 
(Santiago 1992).  This shows the inhibitory GABAergic path from the striatum to the SN and the 
dopaminergic pathway from the SN to the striatum, which is also linked to cocaine reward or 
related behaviors. The mesopallidal dopamine pathway from the VTA to the VP (ventral 
pallidum) is associated with cocaine reward, and is modulated by the GABAergic pathway from 
5the NA to the VP (Gong 1998).  Phaclophen, a GABAB antagonist, increased DA input from the 
NA when injected into the VP (Gong 1998).  As seen in Figure 1, the GABAergic input from the 
NA affects the inputs from the VP to the thalamus, which further code for motor behavior (Koob 
1988).  
Figure 1 Neural circuitry involved in drug reward and drug seeking. GABA-purple, glutamate-
red, dopamine-blue.  VP-ventral pallidum, VTA-ventral tegmental area, NAc-nucleus accumbens 
core, PFC-prefrontal cortex (including anterior cingulate), rBLA-rostral basolateral amygdala, 
Hipp-hippocampus, dmnThal-dorsomedial nucleus of the thalmus. Dashed lines represent 
pathways not clearly proven yet. 
Activation of GABAB heteroceptors and autoreceptors in the BLA inhibit both 
glutamatergic and GABAergic transmitter release into the BLA at low intra-BLA doses, but 
increase excitation of BLA neurons at high doses (Yamada 1999).  GABAB modulation of the 
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6BLA may be involved with the acquisition of fear conditioning or storage of aversive memories 
(Yamada 1999).
A low dose of GABA agonist could reduce activation of the BLA by glutamatergic inputs 
such as the hippocampus, and thus decrease activation of the NA core or PFC by the BLA’s 
glutamatergic projections.  
GABAB receptors mediate synaptic plasticity in the hippocampus, with low levels of 
activation inhibiting long term potentiation (LTP) and high levels inducing LTP (Davies 1991).  
GABAB receptors are also involved in presynaptic inhibition in the cerebellum (Dittman 1997). 
Thus, GABA agonists could modulate contextual learning or motor activities such as balance.
Reward/reinstatement circuitry
The mesocortical (VTA to the PFC), mesolimbic dopamine (VTA to the NA), and 
mesopallidal (VTA to VP) systems have been implicated as mediating drug reward circuitry. 
Relapse, which is defined as drug taking in abstinent user that is triggered by something, is 
mediated by separate circuitries than those mediating drug reward.
There are three types of relapse:  cue-primed stress-primed, or drug-primed.  The 
reinstatement circuitries are distinct for each, but may all end with the glutamatergic pathway 
from the prefrontal cortex (anterior cingulate) to the NA (core) (Kalivas 2003). Several studies 
have implicated the BLA and the PFC as mediating cue-induced reinstatement (Kantak 2002, 
McLaughlin 2003, Weissenborn 1997).  When shown a videotape of cocaine related stimuli, 
cocaine users, compared to naïve subjects, had increased activation of the BLA, orbitofrontal 
cortex, and the anterior cingulate that coincided with reports of craving (Childress, 1999).  
7Studies point to cue-primed reinstatement circuitry beginning at the dopaminergic output 
from the VTA to the BLA, continues from the BLA to the anterior cingulate via a glutamatergic 
projection, and finishing with the glutamatergic projection from the anterior cingulate to the core 
of the NA (Kalivas 2003).
Most cue-primed reinstatement studies have used a discrete cue paired with cocaine 
administration.  Discrete conditioned cues (CS+), which are paired with reward delivery, when 
presented independent of cocaine self-administration, will reinstate extinguished responding
(responding that has ceased due to lack of reward being paired with the responses), but only for 
the first trial (de Wit 1981).  Discriminative cues  (DS+) signal reward availability, and can be 
contextual or discrete. A noncontingent discrete DS+ has been shown to be more effective as a 
reinstator of drug seeking behavior than a noncontingent discrete CS+ (Yun 2003). Contextual 
cues are as potent stimuli as discrete conditioned cues for inducing reinstatement .  Human 
cocaine users associate discrete as well as contextual cues from the environment with cocaine 
use.  In cocaine-extinguished animals that were reinstated by a contextual DS+, an increase in 
Fos protein expression was seen in the BLA and mPFC (Ciccocioppo 2001).  This effect was 
seen even after 4 months of abstinence, showing how contextual cues have the powerful ability 
to cause cravings (uncontrollable desires for the drug) and relapse, and showing that long-term 
changes in neural plasticity are involved.  To make a better model to study cocaine cravings, in 
this study, an odor/visual contextual DS+ that was paired with availability of cocaine self-
administration was used.
The circuitry for cue-induced reinstatement is further differentiated, with the BLA being 
involved only with discrete cue reinstatement, while areas such as the anterior cingulate and the 
NA core seem to be involved with contextual cue reinstatement (See 2002).  As investigated with 
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contextual DS+, and decrease upon presentation of a discrete DS+ (Kalivas 2003).  DA was 
found to increase in the NA as well as the amygdala upon presentation with a contextual DS+ 
(white noise) (Weiss 2000). Rats that had discrete cocaine cues (light + tone) paired with cocaine 
injections had reduced glutamate levels in the NA core when these cues were not present as 
compared to rat that received cocaine but not the cues (Hotsenpiller 2001).  Only the cocaine/cue 
paired group had increased glutamate levels in the NA core when the CS+s were presented 
(Hotsenpiller 2001). Systemic baclofen pretreatment inhibited a stimulus-evoked glutamate 
increase in the NA core (Hotsenpiller 2003).  
More specifically, it appears that only the rostral portion of the BLA plays a role in cue-
induced reinstatement, while the caudal portion regulates maintenance of cocaine self-
administration (Kantak 2002). The NA is similarly differentiated.  In response to non-contingent 
presentations of a CS+ (light), DA was increased only in the NA core, and not the NA shell, 
although DA was increased in both areas during the maintenance of cocaine self-administration 
(Ito 2000). The rostral BLA was found to project to the NA core and not NA shell (Groenewegen 
1990).  This clearly implicates the glutamatergic pathway from the rostral BLA to the NA core in 
cue-induced reinstatement.  D1 antagonists but not D2, AMPA or NMDA antagonists in the 
BLA blocked cue-induced reinstatement (See 2001, Ciccocioppo 2001) This indicates that a 
dopaminergic, and not glutamatergic input to the BLA mediates cue-induced reinstatement.  
Inactivation of the BLA, using tetrodoxin, was found to block acquisition of associations 
between CS+s and cocaine, and thus inhibited cue-induced reinstatement (See 2003).
Cocaine primary reward and secondary reinforcing rewards are processed separately, 
with primary reward activating the NA and secondary reward activating the BLA in a cue-
9induced reinstatement model (Grimm 2000).  Inhibiting the NA only reduces cocaine self-
administration while inhibiting the BLA only reduces cue-induced cocaine-seeking behavior 
(Grimm 2000).
The PFC is able, through mechanisms not clearly known, to inhibit the BLA (Rosenkranz 
2002).  It is thought that lack of inhibitory tone in the amygdala can lead to cue-induced 
reinstatement (Quirk 2003).  Thus, a GABAergic therapeutic, applied locally to the amygdala or 
PFC may prevent drug relapse (Quirk 2003).
The hippocampus, along with the BLA and PFC, may also play a large role in cue-
induced reinstatement.  While the BLA regulates reinstatement induced by discrete stimuli, the 
hippocampus may regulate the motivational aspects of contextual stimuli (Everitt 2002).  
However, the hippocampus may only be involved in acquisition of the drug seeking, and not 
reinstatement of cocaine self-administration. Inactivation of the ventral or dorsal subiculum after 
extinction did not have an effect on cue-induced reinstatement, perhaps because the context 
associations to the drug/cue pairing were so well learned they depended on non-hippocampal 
mechanisms (Black 2004).  
The PFC, BLA, and hippocampus may all modulate cue-induced reinstatement through 
separate glutamatergic projections to the NA core (Everitt 2002).  Thus, the drug context could 
activate the hippocampus, the discrete drug cues could activate the rostral BLA, and the PFC 
could be activated by cravings, all of which would activate the NA core.  There is a GABAergic 
efferent from the NA to the ventral pallidum (VP), and this can activate motor pathways which 
would lead drug seeking behaviors (Koob 1988). 
Baclofen
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Baclofen’s actions are moderately long (as expected given the GABAB target of this 
drug), as suppression of cocaine responding lasts on average for 4 hrs (Roberts 1997). Systemic 
baclofen is more effective at suppressing cocaine responding at low doses rather than high doses, 
but is useful across many reinforcement schedules.  Baclofen dose-dependently reduced 
maintenance of cocaine responding of both 0.2mg/kg and 0.4 mg/kg cocaine infusions on a FR1 
schedule, although the effect was stronger at the lower dose cocaine infusion (Campbell 1999).  
Baclofen (2.5-10 mg/kg) also dose-dependently reduced cocaine responding on an FR5 schedule 
(Shoaib 1998). A baclofen dose of 2.5 mg/kg was shown to reduce maintenance of cocaine self-
administration on a progressive ratio schedule across different unit-doses (0.18, 0.37, 0.75, 1.50 
mg/kg) of cocaine (Roberts 1996).  Baclofen dose-dependently reduced maintenance of cocaine-
self administration (1.5 mg/kg unit-dose) on a progressive ratio schedule but had no effect on 
food self-administration (Roberts 1996).  Using a discrete trials paradigm on an FR5 schedule, 
baclofen (1.25, 2.5, 5.0 mg/kg) suppressed cocaine (1.5 mg/kg) intake (Roberts 1997). 
Together, these data suggest that baclofen may be effective at decreasing the hedonic 
(pleasurable) properties of cocaine, while preserving the rewarding properties of natural rewards 
such as food.  
Baclofen has been shown to work locally to reduce cocaine self-administration. Intra-
VTA and intra-NA baclofen attenuated cocaine self-administration on a FR5 schedule, but intra-
striatum baclofen had no such effect (Shoaib 1998). Intra-VTA baclofen also reduced 
maintenance of cocaine self-administration on a PR schedule, but intra-striatal and intra-NA 
baclofen only reduced maintenance of cocaine self-administration at very high doses of baclofen 
(Brebner 2000b). Intra-VTA baclofen blocks the motor effects of cocaine and blocks 
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sensitization to cocaine (Kalivas 1990).  Intra-VTA, striatum, or NA baclofen did not have any 
effect on food self-administration on a FR5 schedule (Brebner 2000b). 
Baclofen’s utility in reinstatement has also been investigated.  Baclofen dose-dependently 
reduced cocaine-induced reinstatement after a 3.2 mg/kg cocaine-prime was given (Campbell 
1999). Systemic baclofen attenuated locomotion conditioned to a combined light/sound stimulus 
(Hotsenpiller 2003).  However, no studies have investigated baclofen’s affects on cue-induced 
reinstatement of cocaine-seeking or self-administration until now.  
Possible effects of GABAB receptor activation in a cocaine self-administering animal
Incentive salience, which is the learned motivational properties of a stimulus, promotes 
drug seeking in a self-administering animal.  GABAB agonists should reduce incentive salience. 
In an animal that is self-administering with a conditioned cue present, GABAB agonists should 
be less effective at reducing incentive salience because there is a compound effect of drug and 
drug-cue salience.  GABAB agonists are less effective at reducing high doses of cocaine self-
administration, and this reflects an inability to reduce high levels of salience.  
Value of GABAB agonists as a therapeutic for drug-seeking
Cocaine exerts its rewarding effects mainly by blocking the dopamine reuptake pump, 
thus increasing the amount of dopamine (DA) available at the synapse.  Currently, there are no 
pharmacological therapeutics available on the market to treat cocaine addiction.  GABAB
agonists, specifically baclofen, have been targeted as a potential therapeutic.  Priming injections 
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(1.25, and 2.5mg/kg i.p.) of baclofen did not cause reinstatement of cocaine self-administration
in rats,  indicating that this drug has little abuse liability and would not cause drug relapse 
(Campbell 1999). 
Human clinical trials 
Baclofen, marketed as Lioresal, is used in humans as a therapeutic for spacticity, which is 
a condition in which muscles remain contracted for long periods of time when in fact they should 
be relaxed (Brebner 2002).  Baclofen has muscle relaxant properties, because it inhibits 
excessive glutamate release in the spinal cord which would cause muscle contraction (Brebner 
2002).  
A PET study showed cocaine users given baclofen 1-2 hrs before watching a video of 
cocaine cues showed reduced cocaine craving and no activation of the anterior cingulated or 
amygdala, cited in Brebner et. al 2000b (Childress 2002)
In a study of 35 cocaine users receiving placebo + counseling and 35 users receiving 
baclofen + counseling for 16 weeks, baclofen significantly increased over time the probability of 
cocaine free urine samples, but had no effect on reports of cocaine craving (Shoptaw 2003).  This 
shows that baclofen can compound any decreases in drug use caused by psychotherapy or 
counseling. 
In a more recent study of 7 recent cocaine users, baclofen administered 1.5 hours before 
intranasal cocaine administration had no effect on the subjective rewarding effects of cocaine or 
cardiovascular changes (Lile 2004).  Baclofen in these instances may not work because the users 
were not trying to be abstinent, and also because this was a one day, acute trial (Brebner 2002).  
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Baclofen may work better as an anti-relapse agent than to reduce euphoria from acute cocaine 
self-administration (Brebner 2002). 
In summary, these clinical trials indicate that baclofen as a therapeutic for drug seeking 
holds potential.  However, there is a need to elucidate why baclofen works better to control 
cravings in abstinent rather than current drug users. 
Polydrug efficacy
Baclofen has also been shown to reduce cocaine, alcohol, heroin, morphine, nicotine, and 
methamphetamine self-administration in rats,, which shows its utility as a therapeutic for poly-
drug users.  Intra-VTA baclofen reduced heroin self-administration and nicotine self-
administration (Xi 1999, Corrigall 2000).  Systemic baclofen reduced nicotine self-
administration on both fixed and progressive ratio schedules without affecting food responding 
(Paterson 2004).  Systemicly administered baclofen reduced cocaine, morphine, or nicotine-
induced increase in NA dopamine (Fadda 2003).  Methamphetamine self-administration was 
decreased by systemic baclofen as well (Ranaldi 2002).  Systemicly administered baclofen also 
reduced ethanol self-administration, but potentiated its sedative effects (Besheer 2004).  This 
indicates that baclofen may not be a safe therapeutic for cocaine addicts who drink at the same 
time or cocaine abstainers who may drink in place of taking cocaine.  
Baclofen motor side effects
Systemicly administered baclofen acts on the peripheral nervous system as well as the 
central nervous system, and can cause muscle relaxation and sedation.  The higher the dose of 
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baclofen used, the greater the locomotive deficits caused.  A 5.0 mg/kg dose of baclofen greatly 
reduces spontaneous locomotion (McManus 1991).  Baclofen at high doses (3, 6 mg/kg), but not 
a medium dose (1 mg/kg), reduced open field activity, a measure of exploratory behavior 
(McNamara 1995).  Similarly, a 5.0 mg/kg dose of baclofen significantly reduced open field 
activity, a 2.0 mg/kg dose produced a strong trend towards decreased activity, and a 1.25 mg/kg 
dose had no effect (Hotsenpiller 2003).  Baclofen may increase locomotion at medium doses, 
since a 1.25 mg/kg dose increased spontaneous activity in a separate test (Hotsenpiller 2003).  
Pretreatment with baclofen (3.2 mg/kg) under a concurrent food and cocaine self-
administration schedule decreased cocaine responding but not food responding, which suggests 
that baclofen’s reduction of cocaine responding was not due to a motor deficit at that dose 
(Brebner 2000a).   At moderate doses, baclofen affects motor behavior differently on different 
tasks, suggesting that motivational aspects may overcome motor deficits (McNamara 1995, 
Hotsenpiller 2003). Therefore it is important to assess non-specific motor effects of GABAB
activation in the present reinstatement context.
Effects of baclofen on motivation and learning
High doses of baclofen (2.5 mg/kg) inhibited certain aspects of male behavior before 
copulation, and a 5.0 mg/kg dose inhibited copulation (Paredes 1989). Baclofen also inhibited 
female lordosis behavior at a dose of 5.0 mg/kg (Agmo 1989). The results of these studies show
that baclofen at lower doses can reduce incentive salience, but at higher doses, can cause motor 
impairment. 
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Baclofen has been shown to either impair or enhance working memory and spatial 
learning in rats depending on the dose (McNamara 1995)  This shows that baclofen may be 
having beneficial or detrimental impacts depending on the dose used.  
Hypotheses
This study will test the following hypotheses: 
1) baclofen decreases cue-induced reinstatement of cocaine self-administration,
indicating involvement of GABAB receptors in modulation of drug cravings.
2) baclofen increases negative affective reactions to cocaine-associated stimulus 
in an odor reactivity test, indicating involvement of GABAB receptors in 
modulation of drug reward.
3) baclofen has no effect on feeding behavior, indicating that GABA B receptors 
are not involved in modulating natural appetitive behaviors such as eating or 
drinking.  
Materials and Methods
Male Wistar rats (n = 11) (Charles River Co.) weighing between 367 and 602 g were 
housed individually or in pairs on a reverse light cycle (light off at 1000, light on at 2200).  All 
testing was done during the dark phase of the cycle (1100-1700).  Food and water were available 
ad libitum except during initial magazine training.  All procedures followed the strict guidelines 
of the Boston College IACUC and Animal Care Facility.
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Magazine training
Animals were restricted to 20 g of food per day and tested in standard operant boxes 
(Coulbourn Habitest model E10-18NS).  On the right wall there were two nosepokes and a 
central trough in which pellets were released.  The operant boxes were enclosed in sound 
attenuating cabinets.  A computer using Graphic State Notation software version 1.013 
(Coulbourn Instruments) connected to Habitest Lincs collected the data.  Animals were trained 
on a fixed ratio (FR1) schedule of reinforcement to nosepoke for a 45 g food pellet. Animals had 
a 1 minute time-out period, signaled by the house light, before trials began. A yellow light 
randomly illuminating either the right or left nosepoke indicated which nosepoke would be 
reinforced.  A tone signaled the reinforcement.  After each reinforcement there was a 10 second 
time-out period until the next trial. Sessions lasted either 30 minutes or after 38 reinforcements, 
whichever came first.  Animals were considered fully trained when they completed all 38 
reinforcements in less than 30 minutes for two consecutive days. The timing and number of 
active nosepokes and food rewards was measured.
Surgery
Animals were anesthetized using 2-5% isoflurane in oxygen.  Animals had silastic tubing 
catheters implanted into their right jugular veins (Caine 1993).  These implants were secured 
subcutaneously on the animals’ backs.  Animals began operant training one day after surgery. 
Catheters were flushed with a heparin/sucrose solution weekly on weeks that no self-
administration trials were run in order to maintain catheter patency.
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Drugs
Cocaine-HCl (Sigma-Aldrich) and baclofen (Sigma-Aldrich) were dissolved in sterile 
saline.  
Odorants
A volume of 0.1 mL of either extract of peppermint or banana was placed on a gauze 
square placed inside an odor vesicle.  The vesicles were covered with a wire mesh top so that the 
odor could escape but the animals could not taste or touch the odor.  The banana odor vesicles 
had taller tops than the peppermint odor vehicles so that animals could distinguish between them 
both visually and olfactorally.
Self-administration
The odor vesicle (DS+) was placed in the back left corner of the operant box immediately 
before trials began. A Razel syringe pump, situated outside operant boxes and connected with 
silastic tubing to a swivel line connector which was connected to the animal’s cannulas, 
administered the infusions. A 1 minute time-out period, indicated by the house light, occurred 
before trials began.  A blinking light indicated that the left nosepoke would be reinforced.  
Animals were reinforced on an FR1 schedule with an intravenous cocaine infusion (0.375 mg/kg 
in 0.15mL over 4 seconds) signaled by a concurrent tone.  There was a 10 second time-out 
period between trials, and sessions lasted for 30 minutes. The number of responses on active and 
inactive nosepokes, as well as the number of cocaine infusions was measured. 
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Drug holiday 
The drug holiday occurred immediately after the five sessions of cocaine self-
administration.  For five sessions animals received food reinforcement on an FR1 schedule as 
mentioned above under magazine training, except that food was available ad libitum.  Animals 
were not given any cocaine during this drug holiday, nor was the DS+ present.  The food 
reinforced sessions occurred in the same operant boxes as cocaine reinforced sessions previously 
did.  All cues except for the odor DS+ were ambiguously associated with both food and cocaine. 
The timing and number of active nosepokes and food rewards received was measured.
Reinstatement
The reinstatement sessions occurred after the drug holiday period.   Animals followed the 
cocaine self-administration paradigm, with the DS+ present, for 3 days. The number of responses 
on active and inactive nosepokes was measured.
Baclofen pretreated cocaine self-administration
The baclofen pretreatment cocaine self-administration sessions occurred after the three 
days of baseline reinstatement sessions.  Intraperitoneal (i.p.) injections were given 30 minutes 
prior to cocaine self-administration sessions.  On the first day, and every subsequent odd session, 
animals received a saline pre-treatment.  On the days in between, animals received either a saline 
or 0.2, 1.0, or 5.0 mg/kg baclofen pretreatment.  All animals received all doses of baclofen unless 
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there was a failure in catheter patency. Doses were ordered in a randomized complete block 
design.
Baclofen pretreated food self-administration
The baclofen pretreatment food self-administration sessions occurred after the baclofen 
pretreatment cocaine self-administration sessions.  Intraperitoneal (i.p.) injections were given 30 
minutes prior to FR1 food reinforcement sessions (same method as during drug holiday period).  
On the first day, and every subsequent odd session, animals received a saline pre-treatment.  On 
the days in between, animals received either a saline or 0.2, 1.0, or 5.0 mg/kg baclofen 
pretreatment.  All animals received all doses of baclofen unless there was a failure in catheter 
patency. Doses were ordered in a randomized complete block design.
Odor reactivity tests
Animals were retested for odor preference after the acquisition, drug holiday, and 
reinstatement phases of self-administration behavior were each completed.  The method 
consisted of placing animals individually in large plastic cages during the dark cycle.   The DS-
(unconditioned odor vesicle) was placed in the front left corner of the cage and the DS+ 
(conditioned odor vesicle) was placed in the back right corner of the cage.  Each 15 minute trial 
was videotaped using nightvision.  Videotapes were manually scored for latency and frequency 
of contact with the DS+ and DS- odor vesicles.  Movement or burying of the odor vehicles was 
also noted as a checklist measure. 
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In order to test the effects of baclofen on reinstatement of cocaine-seeking behavior 
without the confound of simultaneous cocaine self-administration, animals were given either a 
saline or baclofen pretreatment 30 minutes prior to the odor reactivity test.  
Statistics
Results were analyzed with ANOVA using SPSS  with experimental day, experimental 
phase and baclofen dose as within subjects factors.  Significant interaction effects were further 
explored using simple main effects analysis.  
Results 
Figure 2 Mean nosepoke responding during cocaine acquisition and reinstatement  
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Cocaine self-administration: acquisition and reinstatement after a drug holiday 
A significant main effect of response type (active vs. inactive nosepoke) on rate of 
operant responding [F(1,10)=92.8, p<0.0001] was found.  Mean active nosepokes across 
all eight sessions was 8.7, while mean inactive nosepokes for all eight sessions was 4.4.  
Specific responding for the drug was higher than non-specific responding, indicating 
nosepokes in the nosepoke paired with cocaine was a proper measure of drug seeking 
behavior. In addition, any changes in the number of active nosepokes correlated with a 
respective change in the number of inactive nosepokes, indicating that respective 
increases or decreases in locomotion, rather than a change in the ability to discriminate 
the correct nosepoke, caused these changes. Mean active nosepokes on the first and last 
session were equal, indicating self-administration stabilized by the end of five days. 
A significant main effect of experimental day on the number of nosepokes  
[F(7,70)=3.1, p<0.01] was found.  This was reflected in part by a minimum response rate 
of 4.3 per session during the acquisition phase (range 4.3 - 11.5 responses) and a 
maximum of 11.9 during the reinstatement phase of the study (range 9-11.9 responses), 
as seen in Figure 2.  
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Figure 3 Effect of baclofen pretreatment on mean active and inactive nosepoke 
responding during reinstatement (as % of baseline), *p <0.01 
Figure 4 Effect of baclofen pretreatment on mean (±SEM) cocaine infusions during 
reinstatement 
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Figure 5 Effect of baclofen pretreatment on mean infusion rate over time during 
reinstatement (as % of baseline)
Figure 6 Effect of baclofen pretreatment on mean inter-infusion intervals during 
reinstatement (as % of baseline) 
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Figure 7 Effect of baclofen pretreatment on mean latency of cocaine infusions during 
reinstatement (as % of baseline) 
Figure 8 Effect of baclofen pretreatments on mean time of last cocaine infusion during 
reinstatement (as % of baseline)  
Effect of baclofen on reinstatement of self-administration 
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There was a significant main effect of type (active vs. inactive) of operant 
response [F(1,8)=23.1, p<0.001], as seen in Figure 3.  This supports the cocaine 
acquisition and reinstatement results which suggested that nosepokes in active nosepoke 
paired with cocaine reflected drug seeking behaviors.   
A significant interaction of response type with experimental day [F(5,40)=2.5, 
p<0.05] also occurred.  This interaction was further explored by computing simple main 
effects for the individual days which reflected both baseline periods and days on which 
rats were treated with 0, 0.2, 1 or 5 mg/kg doses of baclofen.  The 0.2 mg/kg dose, but 
none of the other three pretreatments, produced a significant decrease in drug responding 
[F(1,9)=5.8, p<0.05] relative to the previous saline pretreatment baseline day.  This can be 
interpreted as a low dose-dependent suppression of drug seeking behavior by baclofen.   
A 5.0 dose of baclofen decreased, although insignificantly due to low sample size, 
both active and inactive nosepoke responding, indicating a possible motor deficit.  While 
both the 0.2 and 1.0 doses of baclofen slightly reduced inactive nosepokes, only the 0.2 
dose reduced active nosepokes.   
A 0.2 dose of baclofen greatly reduced responses in the first, second, and third 
minutes of sessions compared to the effect of the saline dose.  This low dose of baclofen 
never caused the mean infusion rate to be more than 100% of baseline at any minute, as 
seen in Figure 5, indicating that this dose was consistent over time at reducing cocaine 
intake.  Although the 1.0 dose of baclofen reduced the first 4 minutes of cocaine intake as 
well as the 0.2 dose, overall it did not decrease cocaine intake because it increased cocaine 
intake greatly at later time points.   
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A 0.2 dose of baclofen reduced the number of infusions received within 1 or 2 
minutes of each other, as seen in Figure 6.  A 1.0 dose of baclofen, although shown to 
have no effect on mean number of infusions received (Figure 4), did lengthen the time in 
between infusions, as 400% more infusions than baseline occurred 5 minutes apart from 
each other.   
The 0.2 mg/kg dose of baclofen insignificantly increased the latency to first cocaine
infusion, as seen in Figure 7. The 5.0 mg/kg dose also increased latency, but that was due to a 
probable motor deficit.  The latency to infusion ranged from 1.7 to 23.4 minutes.  No dose of 
baclofen had a significant effect on the timing of the last cocaine infusion, as seen in Figure 8.   
Figure 9  Mean active nosepokes during magazine training (as % of previous session) 
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Figure 10  Mean active nosepokes for food during drug holiday (as % previous session) 
Food self-administration:  magazine training and drug holiday 
Food self-administration stabilized over time during magazine training, as seen in 
Figure 9.  There was no significant effect of experimental day on food responding.  Mean 
nosepokes ranged from 36-83 responses.  Animals on a drug holiday responded at a stable rate 
for food, as seen in Figure 10.  There was no significant effect of experimental day on food 
responding.  Mean nosepokes ranged from 55-66 responses. 
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Figure 11 Effect of baclofen pretreatment on mean active nosepokes for food (as % of 
baseline)
Figure 12 Effect of baclofen pretreatment on mean latency of nosepokes for food (as % 
of baseline) 
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Figure 13 Effect of baclofen pretreatment on mean duration of food self-administration 
trials (as % of baseline) 
Effects of baclofen on food-self administration 
There was no significant effect of baclofen doses (0.2, 1.0 or 5.0 mg/kg) on food 
responding, as seen in Figure 11.  Mean nosepokes ranged from 34-65 responses.  
Baclofen dose-dependently increased, although insignificantly, the latency of food 
self-administration as seen in Figure 12.  A 5.0 dose of baclofen increased latency to 
nosepoke to 825% of baseline, which clearly shows the motor impairment caused by this 
dose.  Supporting this, Figure 13 shows that a 5.0 mg/kg dose of baclofen increased the amount 
of time needed to complete the food self-administration sessions by 267%.   
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Figure 14 Effect of baclofen pretreatment on frequency of contact with odor vesicles 
Figure 15 Effect of baclofen on latency to contact odor vesicles 
Effects of baclofen on cocaine-seeking behavior in the odor reactivity tests 
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Baseline testing revealed that there was no preference for either odor before 
cocaine-acquisition.  Frequency of contact with the odor vesicles increased gradually 
over baseline, post-acquisition, and drug holiday phases of the study, as shown in Figure 
14.  Latency to contact data, as seen in Figure 15, correlated well with frequency of 
contact data across conditions for both DS+s used.  This indicates that the DS+ being 
either banana or peppermint did not create a bias for or against contact with the DS+ after 
post-acquisition, drug holiday or reinstatement. 
The saline pretreated group decreased contact with both the peppermint and 
banana DS+s during the second reinstatement trial.  This cannot be explained by an 
inability for the DS+ to trigger drug-seeking behavior after the first reinstatement trial, 
because the saline group responded at high rate (mean 6.3) for cocaine during 
reinstatement self-administration sessions, and the latency of first infusion was 
unaffected. 
The nature of the conditioned response to the DS+ was in the direction of cue 
avoidance.  For the group that was exposed to the peppermint DS+, cocaine acquisition, 
reinstatement, and saline pretreated reinstatement caused a decrease in frequency of 
contact as compared to the previous trial.  For the group that was exposed to the banana 
DS+, although contact was increased after conditioning, contact was decreased after 
reinstatement and after reinstatement with a saline pretreatment.  In both DS+ groups, a 
drug holiday increased contact with the DS+. This indicates that overall there was a 
conditioned avoidance response to the DS+ when it was banana or peppermint.   
Baclofen had no effect on frequency of contact with either of the conditioned odor 
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vesicles (DS+) or unconditioned odor vesicles (DS-).    
Baclofen had no effect on latency to contact with the conditioned odor vehicle (DS+) 
when it was peppermint.  However, when the conditioned odor vehicle (DS+) was banana, a 1.0
dose greatly increased the latency to contact as compared to the saline treated animals.  This
discrepancy between how baclofen affected latency to approach the two DS+s could have been 
due to low sample size in each condition.  Also, the saline pre-treated animals had different
patterns of DS+ latency in the post-acquisition, extinction, and reinstatement phases, thus
making them an inadequate control for the baclofen pretreated group.  
Discussion
Novel drug holiday instead of extinction
A novel drug ‘holiday’ was used in this study instead of the usual ‘extinction’ period, in 
which animals are put in the same operant box and given saline instead of drug when they make 
operant responses.  This ‘extinction’ period is not a valid human model, as it is unlikely that a 
human would go to the same drug dealer or drug taking environment and not buy or take drugs.  
In this study, the drug holiday consisted of animals self-administering food instead of cocaine, in 
the same operant box without the DS+ associated with cocaine availability.  This is more 
relevant to a human model because humans trying to abstain will have to perform normal daily 
functions in the same area they live in, but will probably be trying to avoid cues such as drug 
paraphernalia or the street from which they bought drugs.  However, re-exposure to these cues, 
voluntarily, or involuntarily (perhaps by accident or by contact with a person a user used to do 
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drugs with), can trigger relapse.  The reintroduction of the DS+ following the drug holiday may 
have contributed to cue-induced reinstatement in the model used in this study.  
In this model, responses for cocaine self-administration instead of drug-seeking (here 
defined as responding for saline or cues) were used as the measure of reinstatement by the cue.  
This is again more relevant to the human model because humans reintroduced into a drug-taking 
environment will not be given saline in exchange for their money.  This model is not confounded 
by cocaine self-administration, because mean cocaine infusions over time in the saline condition 
never increased higher than the mean infusions in the first minute. However, since dopamine 
levels are elevated by cocaine, it is hard to disentangle which brain circuitries are activated by 
hedonic properties of cocaine and which are activated by the drug associated cues in this model 
(Bouton 2002).  However, it may not be necessary to.  Most humans that relapse are triggered by 
a combination of drug associated cues and internal cues from the drug taking.  Crombag et. al. 
(2002) stressed the need for studies to look at the interplay between contextual cues (DS+s), 
discrete cues (CS+s), and drug taking behaviors, so that therapeutics can effectively reduce the 
effect all three have on a drug user.  This study addressed those needs. 
Effects of baclofen on locomotion and feeding
Systemic baclofen did not affect feeding or general locomotion, as shown by nosepokes 
for food being maintained at a high rate during magazine training, drug holiday, and baclofen 
pretreatment phases.  However, nosepoking on a FR1 schedule is a relatively low motor skill 
activity as compared to lever pressing, or nosepoking on a progressive ratio schedule, for 
example.  An observable lack of spontaneous locomotion was seen in the two rats pretreated with 
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high dose (5.0 mg/kg) of baclofen in the odor reactivity test.  This depression of locomotion in 
the high dose group which was not significant in the nosepoke FR1 paradigm may have been 
measured accurately in one of the more sensitive paradigms listed above. 
Effects of baclofen on reinstatement of self-administration
A low dose of baclofen (0.2 mg/kg) was effective at attenuating cue-induced 
reinstatement of self-administration as measured by number of infusions or active nosepokes.  It 
did this by reducing mean infusions of cocaine by increasing the latency of infusions and 
decreasing the number of infusions received within 1-2 minutes of each other.  
A 1.0 dose of baclofen had no effect on cue-induced reinstatement as compared to saline.  
High doses (5.0) of baclofen reduced active and inactive nosepoke responding for cocaine, as 
well as increased mean duration of food trials.  A high dose of baclofen also caused decreased 
locomotion in the odor reactivity tests.  
Thus, baclofen reduces cocaine seeking at low levels, then at some medium dose 
threshold begins to increase cocaine seeking to or above baseline levels, and finally at some high 
dose threshold impairs motor ability.  Baclofen’s dose-dependent effects on cocaine seeking 
during reinstatement follow a U-shaped curve until the threshold dose for motor impairment.
Odor reactivity tests
Reynolds et. al. (2002) used a taste reactivity test to measure behavioral affective 
reactions, such as liking or disliking.  In this study, an odor reactivity test was used to separate 
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the hedonic impact of cocaine (liking) from cocaine-seeking (craving). The frequency of 
contact with the conditioned odor vehicle served as a measure of the direction of affective impact 
of cocaine and cocaine-associated stimuli.  Cocaine-associated stimuli can bring mixed feelings 
of craving, fear, and anxiety (Berger 1996).  The fact that DS+ conditioning was in the direction 
of cue avoidance suggest that the rats also experienced this.  Cocaine’s aversive properties 
outweighed its hedonic properties, causing the animals to dislike and avoid the drug-associated 
stimuli, but still self-administer because the animals were craving cocaine.
A study by De Vries et. al. (1998) paired a 30 minute exposure to peppermint odor with 
passive cocaine injections (30/kg) for five days.  On the 7th day, animals were re-exposed to the 
odor DS+ for 25 minutes, and measured for exploratory behavior for an additional 5 minutes in 
an elevated plus maze.  The study concluded that DS+s induce anxiogenic behavior in the same 
way that cocaine itself does, and implicated a role in the HPA axis for it.  
This provides an alternative explanation or even support for the odor cue (DS+) 
avoidance in the present study.  Part of the aversiveness of the conditioned cues was its 
anxiogenic properties.  Since DeVries’s study also used a peppermint odor as a DS+, it provides 
validation for the use of an odor as a DS+ to reinstate cocaine self-administration in the present 
study.  
This also explains why baclofen had no effect on the frequency of contact with the DS+ 
during reinstatement.  Baclofen acts on GABAB receptors, which are not involved in anxiety.  
Benzodiazepines, which reduce anxiety, bind to the GABAA receptor, indicating that baclofen 
because of receptor specificity, could not have reduced or increased the anxiogenic qualities of 
the DS+.  Thus, baclofen did not change the affective “dislike” reaction to the DS+s.  
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Incentive-sensitization explanation
Berridge’s group proposed that dopamine release in response to drug or natural reward-
associated stimuli increase its “incentive salience”, which causes an increase in reward 
“wanting” or “craving” and thus reward-seeking behavior.  An increase in reward salience does 
not necessarily mean an increase in hedonic properties (“liking”) of the reward (Berridge 2002).  
In the present study, cocaine-acquisition and reinstatement caused DS+s to lose hedonic value, 
but increased the incentive salience of the DS+s because there was an increase in cocaine 
responding when the DS+ was present.  Baclofen’s ability to dose-dependently decrease 
cocaine’s and cocaine-associated cues’ incentive salience followed a U-shaped as described 
earlier.  
This clearly implicates a role for GABAB receptor activation in modulating incentive 
salience of the reward or reward-associated cues, but not a role for modulating hedonic or 
anxiogenic properties of a reward or reward-associated cues.  
Dual effect of dopamine on cocaine-seeking
States in which too much dopamine is present, such as cocaine administration or 
presentation of cocaine associated stimuli, increase cocaine seeking (Childress 2000).  However, 
states in which too little dopamine is present, such as cocaine withdrawal, also cause craving 
(Childress 2000).  Thus, there is a need for homeostatic regulation of dopamine levels.  This can 
be reflected by the U-shaped dose-response curve of baclofen’s effects on cocaine-seeking.  
Baclofen pre-synaptically reduces release of neurotransmitters such as dopamine.  At a low dose, 
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baclofen could reduce the increase in dopamine caused by presentation of a cocaine-associated 
stimulus, and thus reduce cocaine seeking.  At a medium dose, baclofen could reduce cocaine-
associated stimulus increases in dopamine to a deficient level and cause the same level of 
cocaine seeking as baseline.  Baclofen at a high dose could decrease levels of dopamine so much 
that motor circuitry, which relies on dopamine, cannot be activated at all, even for purposes other 
than cocaine-seeking.  
Baclofen’s effects on reinstatement circuitry
The Na core releases GABA into the ventral pallidum, and this disinhibits a motor circuit 
and produces reward-seeking behaviors.  Dopaminergic and glutamatergic inputs from areas 
such as the VTA, anterior cingulate, hippocampus, and BLA converge on these GABA neurons.  
GABAB receptors are located presynaptically on these dopaminergic and glutamatergic inputs, 
and activation of receptors on either of these sites could reduce incentive salience.  Alternatively, 
baclofen may have been acting to inhibit the glutamatergic or dopaminergic inputs to the areas 
which output to the NA, such as the BLA or cortex.  As this was a systemic baclofen study, there 
is no way to prove that either theory is correct.  In any case, the net action of baclofen is to 
modulate GABAergic output to the VP and cause increases or decreases in reward-seeking 
behavior.  
Future Directions
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Local injections of baclofen into the anterior cingulate or NA core could be employed to 
further elucidate GABAergic modulation of reinstatement and incentive salience. 
Conclusions
GABAB agonists modulate drug seeking (craving) but not drug reward (liking), indicating 
that circuitries for drug seeking and drug reward are separate.  Thus, as a therapeutic for human 
cocaine abusers, GABAB agonists potentially would be more useful in users trying to be 
abstinent rather than for users that are still taking the drugs.  GABAB agonists would be unable to 
decrease the rewarding effects of cocaine in current users, and thus would not decrease drug use 
or drug seeking in this population.
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